Filing Flows › Comparisons › SNDX vs RIGL
Syndax Pharmaceuticals vs Rigel Pharmaceuticals: SNDX and RIGL compared
Syndax Pharmaceuticals is the larger company: $83.3M of revenue in its latest quarter (Q3 2026) against $80.9M for Rigel Pharmaceuticals (Q3 2026). Syndax Pharmaceuticals is growing faster (+82% against +16% a year earlier). Rigel Pharmaceuticals is more profitable, with an operating margin of 21.1% against -50.3%.
Where the money goes: SNDX and RIGL
Syndax Pharmaceuticals (SNDX) · Q3 2026
Syndax Pharmaceuticals, Q3 2026: revenue $83.3M (+82% year over year), operating margin -50.3%, net loss $49.4M, operating cash flow −$27.3M. The chart follows the revenue to costs, profit and cash.
Rigel Pharmaceuticals (RIGL) · Q3 2026
Rigel Pharmaceuticals, Q3 2026: revenue $80.9M (+16% year over year), operating margin 21.1%, net earnings $13.2M, operating cash flow $34.6M. The chart follows the revenue to costs, profit and cash.
| Syndax Pharmaceuticals (SNDX) | Rigel Pharmaceuticals (RIGL) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $83.3M | $80.9M |
| Revenue growth, Y/Y | +82% | +16% |
| Operating margin | -50.3% | 21.1% |
| Net earnings | −$49.4M | $13.2M |
| Net margin | -59.3% | 16.3% |
| Operating cash flow | −$27.3M | $34.6M |
| Market value | $1.3B | — |
| Analysts’ mean target | $35.45 | — |
Where the revenue comes from
Syndax Pharmaceuticals
- Product: $60.7M (73%)
- Collaboration Revenue: $22.6M (27%)
Rigel Pharmaceuticals
- Product sales, net: $72.3M (89%)
- Contract revenues from collaborations and other: $8.6M (11%)
Questions
Which is bigger, Syndax Pharmaceuticals or Rigel Pharmaceuticals?
Syndax Pharmaceuticals is the larger company: $83.3M of revenue in its latest quarter (Q3 2026) against $80.9M for Rigel Pharmaceuticals (Q3 2026).
Is Syndax Pharmaceuticals or Rigel Pharmaceuticals growing faster?
Syndax Pharmaceuticals is growing faster (+82% against +16% a year earlier).
Which is more profitable, Syndax Pharmaceuticals or Rigel Pharmaceuticals?
Rigel Pharmaceuticals is more profitable, with an operating margin of 21.1% against -50.3%.
More: Syndax Pharmaceuticals earnings · how Syndax Pharmaceuticals makes money · Rigel Pharmaceuticals earnings · how Rigel Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 2, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.